Skip to main content
PMC home page
Indian Journal of Psychiatry logoLink to Indian Journal of Psychiatry
. 2004 Apr-Jun;46(2):150–155.

Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders

RK Chavda 1,*, L Laxmi 1, BS Nair 1, K Gandewar 2
PMCID: PMC2949931  PMID: 21408042

Abstract

Before the 1990s, treatment of psychoses centred on conventional agents whose tolerability was limited by extrapyramidal symptoms (EPS). The past decade has seen the emergence of newer generation of antipsychotic agents. These agents provide better negative symptom efficacy, less impaired cognition and lower risk of extrapyramidal syndromes. Aripiprazole, a new atypical antipsychotic drug, displayed efficacy similar to risperidone and haloperidol in numerous clinical trials. Aripiprazole does not cause significant prolactin elevation and is associated with a low rate of clinically significant weight gain compared with other atypical antipsychotics. Aripiprazole is a study drug for treating schizophrenia and has a novel pharmacologic profile. Aripiprazole provides a new treatment option with limited adverse effects for patients in need of antipsychotic therapy. The present study is a 4-week, open-labelled, randomized postmarketing clinical study conducted using aripiprazole as the study drug. Fixed doses of 15mg of the drug were administered throughout the study. A total of 249 patients with a primary diagnosis of schizophrenia or schizoaffective disorder were randomized. Efficacy measures included the Positive And Negative Syndrome Scale (PANSS) total, PANSS positive, PANSS negative and general psychopathology. Patients were evaluated for efficacy parameters at the end of 2nd week and also at the end of study. Unlike the other antipsychotics, aripiprazole was not associated with significant EPS, increase in body weight or increase in QTc interval. Aripiprazole, effective against positive and negative symptoms, is a safe and well-tolerated potential treatment for schizophrenia and schizoaffective disorder.

Keywords: Aripiprazole, schizophrenia, efficacy, safety

Full Text

The Full Text of this article is available as a PDF (109.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allison D. B., Casey D. E. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62 (Suppl 7):22–31. [PubMed] [Google Scholar]
  2. Andén N. E., Butcher S. G., Corrodi H., Fuxe K., Ungerstedt U. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol. 1970;11(3):303–314. doi: 10.1016/0014-2999(70)90006-3. [DOI] [PubMed] [Google Scholar]
  3. Ban T. A. Pharmacotherapy of mental illness--a historical analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2001 May;25(4):709–727. doi: 10.1016/s0278-5846(01)00160-9. [DOI] [PubMed] [Google Scholar]
  4. Burris Kevin D., Molski Thaddeus F., Xu Cen, Ryan Elaine, Tottori Katsura, Kikuchi Tetsuro, Yocca Frank D., Molinoff Perry B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):381–389. doi: 10.1124/jpet.102.033175. [DOI] [PubMed] [Google Scholar]
  5. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1988 Sep;1(3):179–186. doi: 10.1016/0893-133x(88)90012-7. [DOI] [PubMed] [Google Scholar]
  6. Carlsson A., Waters N., Waters S., Carlsson M. L. Network interactions in schizophrenia - therapeutic implications. Brain Res Brain Res Rev. 2000 Mar;31(2-3):342–349. doi: 10.1016/s0165-0173(99)00050-8. [DOI] [PubMed] [Google Scholar]
  7. Creese I., Burt D. R., Snyder S. H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976 Apr 30;192(4238):481–483. doi: 10.1126/science.3854. [DOI] [PubMed] [Google Scholar]
  8. Emilien G., Maloteaux J. M., Geurts M., Hoogenberg K., Cragg S. Dopamine receptors--physiological understanding to therapeutic intervention potential. Pharmacol Ther. 1999 Nov;84(2):133–156. doi: 10.1016/s0163-7258(99)00029-7. [DOI] [PubMed] [Google Scholar]
  9. Fleischhacker W. W., Meise U., Günther V., Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl. 1994;382:11–15. [PubMed] [Google Scholar]
  10. Gury C., Canceil O., Iaria P. Antipsychotiques et sécurité cardio-vasculaire: données actuelles sur les allongements de l'intervalle QT et le risque d'arythmies ventriculaires. Encephale. 2000 Nov-Dec;26(6):62–72. [PubMed] [Google Scholar]
  11. Iyer R. N., Davis M. D., Juneau P. L., Giordani A. B. Brain extracellular levels of the putative antipsychotic CI-1007 and its effects on striatal and nucleus accumbens dopamine overflow in the awake rat. J Pharm Pharmacol. 1998 Oct;50(10):1147–1153. doi: 10.1111/j.2042-7158.1998.tb03326.x. [DOI] [PubMed] [Google Scholar]
  12. Jordan Shaun, Koprivica Vuk, Chen Ruoyan, Tottori Katsura, Kikuchi Tetsuro, Altar C. Anthony. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002 Apr 26;441(3):137–140. doi: 10.1016/s0014-2999(02)01532-7. [DOI] [PubMed] [Google Scholar]
  13. Kay S. R., Fiszbein A., Opler L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi: 10.1093/schbul/13.2.261. [DOI] [PubMed] [Google Scholar]
  14. Kurzthaler I., Fleischhacker W. W. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry. 2001;62 (Suppl 7):32–37. [PubMed] [Google Scholar]
  15. Lahti A. C., Weiler M. A., Corey P. K., Lahti R. A., Carlsson A., Tamminga C. A. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry. 1998 Jan 1;43(1):2–11. doi: 10.1016/s0006-3223(97)00030-9. [DOI] [PubMed] [Google Scholar]
  16. Leysen J. E., Janssen P. M., Schotte A., Luyten W. H., Megens A. A. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) 1993;112(1 Suppl):S40–S54. doi: 10.1007/BF02245006. [DOI] [PubMed] [Google Scholar]
  17. Millan M. J. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther. 2000 Dec;295(3):853–861. [PubMed] [Google Scholar]
  18. Murray C. J., Lopez A. D. Evidence-based health policy--lessons from the Global Burden of Disease Study. Science. 1996 Nov 1;274(5288):740–743. doi: 10.1126/science.274.5288.740. [DOI] [PubMed] [Google Scholar]
  19. Rao M. L., Möller H. J. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review. Neuropsychobiology. 1994;30(4):160–172. doi: 10.1159/000119156. [DOI] [PubMed] [Google Scholar]
  20. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry. 1999;60 (Suppl 10):5–14. [PubMed] [Google Scholar]
  21. Seeman P., Niznik H. B. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J. 1990 Jul;4(10):2737–2744. doi: 10.1096/fasebj.4.10.2197154. [DOI] [PubMed] [Google Scholar]
  22. Simpson G. M., Angus J. W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–19. doi: 10.1111/j.1600-0447.1970.tb02066.x. [DOI] [PubMed] [Google Scholar]
  23. Stahl S. M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry. 2001 Nov;62(11):841–842. doi: 10.4088/jcp.v62n1101. [DOI] [PubMed] [Google Scholar]
  24. Stahl S. M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry. 2001 Dec;62(12):923–924. doi: 10.4088/jcp.v62n1201. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Psychiatry are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES